Mr. Bill Adams reports

NERVGEN PHARMA EXTENDS THE EXPIRY DATE OF CERTAIN STOCK OPTIONS

A two-year extension of the expiry date of Nervgen Pharma Corp. stock options has been granted to a consultant of the company on April 23, 2021, and July 16, 2021, such that the terms of the options shall be extended from three years to five years following the original grant dates, respectively. All other terms of the options, including the exercise price, remain the same.

About Nervgen Pharma Corp.

Nervgen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis.